Here, we summarize the studies that have described the generation of d16HER2 and its involvement in BC, focusing on HER2-driven tumorigenesis, tumor aggressiveness, stemness, epithelial–mesenchymal transition (EMT) programs, and the response to anti-HER2 biodrugs. This evidence concerns the gene ERBB2 and breast cancer.